Coherus Bio (CHRS) Stock Price, Quote & News

Company Profile

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investi...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 649 3530

Website: www.coherus.com

Address:

333 Twin Dolphin Drive, Suite 600, Redwood City, United States

SomePoorGuy Jun. 24 at 8:54 PM

$CHRS The DOW had a great year and is up 20.33%! CHRS has been boring this past year and is up 97.92%. I suppose boring isn't the end of the world. Looking forward to data drops and any other catalysts released before the next earnings call. Denny stated during the Q1 2026 earnings call, "We look forward to seeing you on our August call, which will be very exciting."

1 · Reply

Grandgustav Jun. 24 at 2:57 PM

$CHRS too our dedicated shorties…

0 · Reply

SomePoorGuy Jun. 23 at 11:10 PM

$CHRS It's nice to see management executing on its supply deal strategy, helping to strengthen the potential for new indications across the pipeline. With that being said, this latest agreement alone isn't enough to significantly change the outlook in my opinion. I'm still focused on what matters most, and thats the data that should be released soon. Until we see meaningful clinical results, I'll remain patient and zee gow this unfolds.

1 · Reply

cdlawton07 Jun. 23 at 9:25 PM

$CHRS good news on the Loqtorzi clinical supply agreement. Might open up another indication at little cost to the company other than supplying the drug. Interesting they haven't done anything similar with tagmo/casdozo since the J&J deal. Maybe they want to keep those assets clean so as to not complicate an acquisition deal. Imagine if CHRS partnered tagmo with a Merck or AstraZeneca compound, an acquirer like J&J probably wouldn't want that. They'd want to be able to pair it with their own internal compounds rather than with competitors.

0 · Reply

BigDaddyCapital Jun. 23 at 8:04 PM

$CHRS lmao tries to pump stock with a collab w Indian company that’s sub $20M company and it closes down 😂😂😂

2 · Reply

calibran_de Jun. 23 at 6:55 PM

$CHRS https://investors.coherus.com/news-releases/news-release-details/coherus-and-zumutor-biologics-announce-clinical-collaboration

0 · Reply

Cowpokecaleb Jun. 23 at 6:16 PM

$CHRS https://www.globenewswire.com/news-release/2026/06/23/3316369/33333/en/coherus-and-zumutor-biologics-announce-clinical-collaboration-to-evaluate-zm008-in-combination-with-loqtorzi-toripalimab-tpzi.html

1 · Reply

Samishere Jun. 23 at 6:11 PM

$CHRS Just a reminder.. Statistically, the vast majority of oncology drugs fail somewhere between Phase 1 and Phase 3.

1 · Reply

Samishere Jun. 23 at 6:07 PM

$CHRS Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi) Oh boy- more Phase I Where’s my pumpers ?

2 · Reply

Grandgustav Jun. 23 at 3:15 PM

$CHRS

1 · Reply

Coherus, Zumutor collaborate for ZM008, Loqtorzi combination study

Jun 23, 2026, 2:00 PM EDT - 1 day ago

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

Jun 4, 2026, 9:55 AM EDT - 20 days ago

Coherus Oncology Transcript: Jefferies Global Healthcare Conference 2026

May 28, 2026, 8:00 AM EDT - 27 days ago

Coherus Oncology Proxy statement: Proxy filing

May 27, 2026, 4:30 PM EDT - 4 weeks ago

Coherus Oncology Transcript: AGM 2026

2026-05-11T23:20:35.000Z - 6 weeks ago

Coherus Oncology reports Q1 EPS (28c), consensus (26c)

May 11, 2026, 5:00 PM EDT - 6 weeks ago

Coherus Oncology Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 6 weeks ago

Coherus Oncology Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 6 weeks ago

Coherus Oncology Quarterly report: Q1 2026

May 11, 2026, 4:05 PM EDT - 6 weeks ago

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

2026-05-11T12:37:08.000Z - 6 weeks ago

Guggenheim starts Coherus with Buy on anti-tumor potential

2026-05-11T10:36:08.000Z - 6 weeks ago

Coherus Oncology initiated with a Buy at Guggenheim

May 5, 2026, 8:00 AM EDT - 7 weeks ago

Coherus Oncology Proxy statement: Proxy filing

May 4, 2026, 9:30 AM EDT - 7 weeks ago

Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026

Apr 20, 2026, 8:00 AM EDT - 2 months ago

Coherus Oncology Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 2 months ago

Coherus Oncology Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 2 months ago

Coherus Oncology Proxy statement: Proxy filing

Mar 10, 2026, 2:50 PM EDT - 3 months ago

Coherus Oncology Transcript: The Citizens Life Sciences Conference 2026

2026-03-09T20:40:57.000Z - 3 months ago

Coherus Oncology reports Q4 EPS (34c), consensus (31c)

Mar 9, 2026, 4:30 PM EDT - 3 months ago

Coherus Oncology Earnings Call Transcript: Q4 2025

Mar 9, 2026, 4:30 PM EDT - 3 months ago

Coherus Oncology Annual report: Q4 2025

Mar 9, 2026, 4:30 PM EDT - 3 months ago

Coherus Oncology Earnings release: Q4 2025

Mar 9, 2026, 4:15 PM EDT - 3 months ago

Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

Mar 4, 2026, 11:50 AM EST - 4 months ago

Coherus Oncology Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:30 AM EST - 4 months ago

Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

Feb 23, 2026, 9:30 AM EST - 4 months ago

Coherus Oncology to Participate in Upcoming Investor Conferences

Feb 17, 2026, 4:11 PM EST - 4 months ago

Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock

2026-02-13T11:50:56.000Z - 4 months ago

Coherus Oncology 28.6M share Spot Secondary priced at $1.75

Feb 12, 2026, 9:18 PM EST - 4 months ago

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

2026-02-12T21:12:06.000Z - 4 months ago

Coherus Oncology announces common stock offering, no amount given

2026-01-22T21:16:58.000Z - 5 months ago

Coherus Oncology initiated with an Outperform at Oppenheimer ahead of readouts

2026-01-22T21:11:03.000Z - 5 months ago

Coherus Oncology initiated with an Outperform at Oppenheimer

Jan 13, 2026, 1:30 PM EST - 5 months ago

Coherus Oncology Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 1:30 PM EST - 5 months ago

Coherus Oncology Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 9:30 AM EST - 6 months ago

Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

2026-01-05T14:51:47.000Z - 6 months ago

Coherus Oncology announces publication highlighting CCR8 antibody tagmokitug

Jan 5, 2026, 9:30 AM EST - 6 months ago

Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

Dec 17, 2025, 1:30 PM EST - 6 months ago

Coherus Oncology Transcript: Biotech Discovery Series

2025-12-08T13:45:59.000Z - 7 months ago

Coherus Oncology announces six-year OS results from Phase 3 JUPITER-02 trial

Dec 8, 2025, 8:30 AM EST - 7 months ago

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

Nov 18, 2025, 5:30 AM EST - 7 months ago

Coherus Oncology Transcript: Jefferies London Healthcare Conference 2025

2025-11-13T22:35:29.000Z - 7 months ago

Coherus Oncology files $150M mixed securities shelf

Nov 13, 2025, 7:00 AM EST - 7 months ago

Coherus Oncology Registration statement: Registration Filing

Nov 10, 2025, 1:15 PM EST - 8 months ago

Coherus Oncology Transcript: UBS Global Healthcare Conference 2025

Nov 7, 2025, 9:00 AM EST - 8 months ago

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

Nov 6, 2025, 5:00 PM EST - 8 months ago

Coherus Oncology Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

Coherus Oncology Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

Coherus Oncology Earnings release: Q3 2025

Nov 6, 2025, 4:14 PM EST - 8 months ago

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 1:54 PM EST - 8 months ago

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

Oct 30, 2025, 8:30 AM EDT - 8 months ago

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 3, 2025, 9:05 AM EDT - 9 months ago

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 1, 2025, 1:00 PM EDT - 9 months ago

Coherus Oncology Transcript: UBS Virtual Oncology Day

Sep 10, 2025, 11:00 AM EDT - 10 months ago

Coherus Oncology Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 1:25 PM EDT - 10 months ago

Coherus Oncology Transcript: Baird Global Healthcare Conference 2025

2025-09-04T11:35:24.000Z - 10 months ago

Coherus Biosciences upgraded to Buy from Neutral at Roth Capital

2025-09-04T11:35:13.000Z - 10 months ago

Coherus Biosciences upgraded to Buy from Hold at Maxim

Aug 7, 2025, 5:00 PM EDT - 11 months ago

Coherus Oncology Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

Coherus Oncology Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

Coherus Oncology Earnings release: Q2 2025

Aug 7, 2025, 4:41 PM EDT - 11 months ago

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 4:45 PM EDT - 11 months ago

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 25, 2025, 7:00 AM EDT - 1 year ago

Coherus Oncology Slides: Corporate Presentation

Jun 4, 2025, 5:30 PM EDT - 1 year ago

Coherus Oncology Transcript: Jefferies Global Healthcare Conference 2025

2025-05-30T12:11:11.000Z - 1 year ago

Coherus Biosciences completes transformation to Coherus Oncology

May 27, 2025, 3:00 PM EDT - 1 year ago

Coherus Oncology Transcript: 6th Annual Oncology Innovation Summit

2025-05-27T12:40:21.000Z - 1 year ago

Coherus Biosciences announces clinical collaboration with STORM Therapeutics

May 20, 2025, 12:00 PM EDT - 1 year ago

Coherus Oncology Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings Call Transcript: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Quarterly report: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings release: Q1 2025

May 12, 2025, 4:15 PM EDT - 1 year ago

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 9:00 AM EDT - 1 year ago

Coherus Oncology Transcript: The Citizens JMP Life Sciences Conference 2025

May 5, 2025, 4:01 PM EDT - 1 year ago

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

May 1, 2025, 5:04 PM EDT - 1 year ago

Coherus to Participate in Upcoming Investor Conferences

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Coherus Oncology Transcript: KOL Event

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Coherus Oncology Press release: KOL Event

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Coherus Oncology Slides: KOL Event

Apr 28, 2025, 10:10 AM EDT - 1 year ago

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 10, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings Call Transcript: Q4 2024

Mar 10, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Annual report: Q4 2024

Mar 10, 2025, 5:00 PM EDT - 1 year ago

Coherus Oncology Earnings release: Q4 2024

Mar 10, 2025, 4:12 PM EDT - 1 year ago

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

Mar 4, 2025, 11:50 AM EST - 1 year ago

Coherus Oncology Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Mar 3, 2025, 8:30 AM EST - 1 year ago

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

Feb 24, 2025, 9:08 AM EST - 1 year ago

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Jan 28, 2025, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Jan 14, 2025, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Jan 14, 2025, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Jan 13, 2025, 8:15 PM EST - 1 year ago

Coherus Oncology Transcript: at 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 8:15 PM EST - 1 year ago

Coherus Oncology Slides: FY 2025

Dec 18, 2024, 8:30 AM EST - 1 year ago

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Dec 4, 2024, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Dec 4, 2024, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Dec 3, 2024, 3:15 PM EST - 1 year ago

Coherus Oncology Transcript: Citi's 2024 Global Healthcare Conference

Dec 3, 2024, 8:00 AM EST - 1 year ago

Coherus Oncology Transcript: Status Update

Dec 3, 2024, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Dec 3, 2024, 7:00 AM EST - 1 year ago

Coherus Oncology Proxy statement: Proxy Filing

Nov 27, 2024, 4:01 PM EST - 1 year ago

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

Nov 6, 2024, 5:00 PM EST - 1 year ago

Coherus Oncology Earnings Call Transcript: Q3 2024

Nov 6, 2024, 5:00 PM EST - 1 year ago

Coherus Oncology Quarterly report: Q3 2024

Nov 6, 2024, 5:00 PM EST - 1 year ago

Coherus Oncology Earnings release: Q3 2024

Nov 6, 2024, 4:01 PM EST - 1 year ago

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 30, 2024, 4:20 PM EDT - 1 year ago

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings Call Transcript: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Quarterly report: Q2 2024

Aug 8, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings release: Q2 2024

Aug 1, 2024, 9:00 AM EDT - 2 years ago

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

Jun 27, 2024, 8:26 AM EDT - 2 years ago

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

Jun 6, 2024, 8:30 AM EDT - 2 years ago

Coherus Oncology Transcript: Jefferies 2024 Global Healthcare Conference

May 30, 2024, 9:00 AM EDT - 2 years ago

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

May 29, 2024, 12:00 PM EDT - 2 years ago

Coherus Oncology Transcript: TD Cowen 5th Annual Oncology Innovation Virtual Summit

May 23, 2024, 5:51 PM EDT - 2 years ago

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2024, 9:00 AM EDT - 2 years ago

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

May 13, 2024, 8:00 AM EDT - 2 years ago

Coherus Oncology Proxy statement: Proxy Filing

May 9, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings Call Transcript: Q1 2024

May 9, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Quarterly report: Q1 2024

May 9, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings release: Q1 2024

May 9, 2024, 4:01 PM EDT - 2 years ago

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 7:30 AM EDT - 2 years ago

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

May 8, 2024, 9:00 AM EDT - 2 years ago

Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

May 1, 2024, 4:30 PM EDT - 2 years ago

Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 24, 2024, 10:02 AM EDT - 2 years ago

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Coherus Oncology Proxy statement: Proxy Filing

Apr 15, 2024, 8:00 AM EDT - 2 years ago

Coherus Oncology Proxy statement: Proxy Filing

Apr 8, 2024, 8:30 AM EDT - 2 years ago

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

Mar 13, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings Call Transcript: Q4 2023

Mar 13, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Annual report: Q4 2023

Mar 13, 2024, 5:00 PM EDT - 2 years ago

Coherus Oncology Earnings release: Q4 2023

Mar 13, 2024, 4:01 PM EDT - 2 years ago

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

Mar 5, 2024, 4:01 PM EST - 2 years ago

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

Mar 4, 2024, 1:00 AM EST - 2 years ago

Coherus Completes Divestiture of Ophthalmology Franchise

Feb 23, 2024, 5:33 PM EST - 2 years ago

Coherus BioSciences Announces New Employment Inducement Grants

Feb 21, 2024, 8:30 AM EST - 2 years ago

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Feb 5, 2024, 8:00 AM EST - 2 years ago

Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP

Jan 22, 2024, 8:30 AM EST - 2 years ago

Coherus Oncology Transcript: Investor Update

Jan 22, 2024, 8:30 AM EST - 2 years ago

Coherus Oncology Press release: Investor Update

Jan 22, 2024, 1:15 AM EST - 2 years ago

Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

Jan 18, 2024, 4:05 PM EST - 2 years ago

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

SomePoorGuy Jun. 24 at 8:54 PM

1 · Reply

Grandgustav Jun. 24 at 2:57 PM

$CHRS too our dedicated shorties…

0 · Reply

SomePoorGuy Jun. 23 at 11:10 PM

1 · Reply

cdlawton07 Jun. 23 at 9:25 PM

0 · Reply

BigDaddyCapital Jun. 23 at 8:04 PM

$CHRS lmao tries to pump stock with a collab w Indian company that’s sub $20M company and it closes down 😂😂😂

2 · Reply

calibran_de Jun. 23 at 6:55 PM

$CHRS https://investors.coherus.com/news-releases/news-release-details/coherus-and-zumutor-biologics-announce-clinical-collaboration

0 · Reply

Cowpokecaleb Jun. 23 at 6:16 PM

1 · Reply

Samishere Jun. 23 at 6:11 PM

$CHRS Just a reminder.. Statistically, the vast majority of oncology drugs fail somewhere between Phase 1 and Phase 3.

1 · Reply

Samishere Jun. 23 at 6:07 PM

$CHRS Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi) Oh boy- more Phase I Where’s my pumpers ?

2 · Reply

Grandgustav Jun. 23 at 3:15 PM

$CHRS

1 · Reply

John1066 Jun. 23 at 1:56 PM

$CHRS I’ve chased up a response on this to get clarity on the tsa liabity. Still not clear for me but interesting that IR have made reference to the intas milestone payments.

0 · Reply

Grandgustav Jun. 22 at 5:44 PM

$CHRS the more i think of it, the more intrigued i am about maybe releasing all three midyear data sets a day before earnings and forcing shorts to get out immediately for our strongest squeeze potential. That also allows data to mature. sucks to wait seven more weeks, but if all three readouts are excellent, kaboom!

1 · Reply

Grandgustav Jun. 22 at 4:18 PM

$CHRS

0 · Reply

simonig1 Jun. 22 at 3:03 PM

$CHRS Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Coherus Biosciences (CHRS) Catie Powers Catie Powers Jun 22, 2026, 04:51 AM There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Boston Scientific (BSX), Coherus Biosciences (CHRS) and Alnylam Pharma (ALNY) with bullish sentiments. Coherus Biosciences (CHRS) In a report released today, Jay Olson from Oppenheimer reiterated a Buy rating on Coherus Biosciences, with a price target of $10.00. The company’s shares closed last Thursday at $1.48. According to TipRanks.com, Olson is a 5-star analyst with an average return of 22.3% and a 48.5% success rate. Olson covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Adlai Nortye Ltd. Sponsored ADR, and Harmony Biosciences Holdings. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Coherus Biosciences with a $8.25 average price target.

0 · Reply

Jack_Nicholson_Truth Jun. 22 at 2:43 PM

$CHRS very interesting. Iborrow says Ib not reporting chrs short data. 😳

2 · Reply

Jack_Nicholson_Truth Jun. 22 at 1:41 PM

$CHRS how dumb do you have to be to short now or sell after waiting this long. Sami and bigdaddy I'm back to 100% gains on those dip buy shares you said to NOT buy. Only a 5 year downtrend since chrs bought tori and a three year base into the 6 data catalyst this year. You see this chart and think you should short it? Lmao Y

0 · Reply

Jack_Nicholson_Truth Jun. 22 at 12:59 PM

$CHRS HERE IS A CHART IF HOW MANY DAYS TIL NEWS. 30M+ SHARES SHORT. NEGATIVE EV FOR CHS-114 AND CASDO. THERE'S 3 AND THEY WILL BE RELEASED SEPERATELY BECAUSE THEY ALL DIFFERENT TRIALS! SO 3X THE % OF ALPHA. forget all the bots❌ and bs online ❌ on reddit, x, HERE. Only list that matters now👇👇

1 · Reply

Thomas105 Jun. 22 at 12:37 PM

$CHRS Oppenheimer updates today 10$

1 · Reply

simonig1 Jun. 22 at 12:08 PM

$CHRS Nice Targets!!! Link: https://www.tipranks.com/stocks/chrs/forecast

0 · Reply

Grandgustav Jun. 21 at 3:16 PM

$CHRS

2 · Reply

Grandgustav Jun. 20 at 4:23 PM

$CHRS If I get a piece of today's early pick-five carryover at Monmouth Park, I'm buying more shares.

0 · Reply

John1066 Jun. 19 at 4:36 PM

$CHRS let you know when i get reply from this but i suspect techno is right.

1 · Reply

Market Cap	90.31M
Revenue (ttm)	266.96M
Net Income (ttm)	28.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	10.68%
Debt to Equity Ratio	-0.20

Volume	1,822,400
Avg Vol	1,708,078
Day's Range	N/A - N/A
Shares Out	115.93M
Stochastic %K	30%
Beta	1.01
Analysts	Strong Sell
Price Target	$5.26